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Six potential GF-I sites which bind an erythroid factor are present in the 5’ and 3’ regions flanking the erythroid-specific transcription unit of 
the human carbonic anhydrase I (HCAI) gene. When two of these sites are placed upstream of a minimal eukaryotic promoter they confer up- 
regulated expression in erythroid over non-erythroid cells. The presence of the erythroid factor in TPA-treated HEL cells m which the level of 
HCAI transcript has greatly decreased and in non-HCAI-expressing KS62 cells suggests that in these cases the presence of the factor is not sufficient 
for HCAI expression. 
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1. INTRODUCTION T4 polynucleotide kinase and [y-32P]ATP and hybridised to 25 pg of 
RNA followed by extension with reverse transcriptase. 
Certain conserved DNA sequence elements to which 
transcription factors bind are necessary for the expres- 
sion of most eukaryotic genes by RNA polymerase II; 
other elements, binding specific trans-acting protein 
factors have been shown to determine cell-specific ex- 
pression [ 11. In erythroid cells, the promoters of globin 
genes contain the conserved ‘TATA’ or ‘CATA’, 
‘CAAT’ and ‘CACCC’ sequence cassettes and recent 
work has identified a sequence motif ‘GATAAG’ (or 
closely related variants thereof) which binds an 
erythroid-specific protein [2-51. This sequence lement 
is conserved across species and is found in either orien- 
tation in the regulatory regions of erythroid-specific 
genes. A cDNA encoding this factor has recently been 
cloned and designated GF-1 [6]. This paper defines the 
erythroid-specific transcription unit of the HCAI gene, 
the expression of which is characteristic of erythroid 
cells of the adult phenotype [7], and examines the bin- 
ding of the erythroid-specific factor to sequences flank- 
ing it. 
Si-nuclease mapping used single-stranded DNA probes generated 
from Ml3 templates [lo]. For 5’-end mapping, aPvuII-Hind111 frag- 
ment containing the first HCAI exon was subcloned into M13mp18 
and the complementary strand synthesised using the above primer. 
For 3’-end mapping, a HindIII-MboI fragment from the 
3’-untranslated region (221-572 bp downstream from the stop 
codon) was subcloned into M13mp19 and synthesis of the com- 
plementary strand initiated using the 17mer Amersham sequencing 
primer. 3 x 10’ cpm of 5’-end probe was hybridised to 15 pg total 
human reticulocyte RNA at 62 or 70°C for 3 h. 1.4 x 10’ cpm of 
3 ‘-end probe was hybridised to 9 pg of RNA for 1 h at 50 or 58°C. 
Si-nuclease digestion was carried out for 2 h at 20°C. 
2.2. Cell lines and tmue culture 
The erythroid cell lines used were KS62 [ll], K562-SAl [12], HEL 
(92.1.7) [13] and mouse erythroleukemic (MEL) cells F412B2 (TK-) 
[14]. K562 have an embryonic/foetal phenotype, the others an adult 
phenotype. All were grown in Dulbecco’s MEM (DMEM) with 10% 
foetal calf serum (Gibco) plus penicillin (100 U/ml), streptomycin 
(lOOgg/ml) and amphotericin B (2.5 pg/ml). Another MEL cell line 
C88 (APRT-) [ 151 was also used and grown in (u-MEM supplemented 
with 10% foetal calf serum and 50 pg/ml diaminopurine. HeLa cells 
were grown in DMEM as above. HL-60 (myeloid) [16] and HUT-78 
(lymphoid) [17] were grown in RPM1 1640 plus 10% foetal calf serum 
with antibiotics and amphotericin B as above. All media were sup- 
plemented with 2 mM glutamine. 
2. MATERIALS AND METHODS 
2.1. Transcription unit mapping 
Total human reticulocyte RNA was prepared by the guanidinium 
hydrochloride/caesium chloride method [S]. Primer extension 
analysis [9] of the 5’-end of HCAI mRNA used a single-stranded 
DNA oligonucleotide primer (3 ’ -CACCAGGACAGACCGTCG- 
GA-5 ‘) complementary to a sequence in the 5 ‘-leader region of the 
HCAI gene (from +33 to +52). The primer was 5’-end labelled with 
HEL cells were induced to undergo a macrophage-like shift by 
treatment with 12-0tetradecanoyl-phorbol-13-acetate (TPA) [18]. 
TPA was dissolved in dimethylsulphoxide (DMSO) and used at 
10m6 M for 4-8 days. Control cultures contained equivalent amounts 
of DMSO (0.01%). 
2.3. Protein preparatron 
Correspondence address: H J .M . Brady, Department of 
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Whole cell extracts used for gel retardation were prepared by 
modification of the method of Dale et al. [19]: frozen cell pellets were 
made of total volume 0.2 ml containing 2-3 x 10’ cells. 1 .O ml ice- 
cold extraction Buffer A (10 mM Hepes, pH 7.9, 0.4 M NaCI, 
1.5 mM MgC12, 0.1 mM EGTA, 0.5 mM DTT, 0.5 mM PMSF and 
5% glycerol) was added to a single pellet for lysis. The lysate was cen- 
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trifuged at 100000 x g at 4°C for 15 min. The supernatant was 
desalted with Buffer B (same as Buffer A but with 50 mM NaCI) on 
a NAP-5 column (Pharmacia) and stored at -70°C. 
Nuclear proteins for footprinting were prepared from 10’ cells 
which were washed twice in phosphate-buffered saline and twice in 
Buffer I (0.05% Nonidet P-40, 10 mM Hepes pH 7.9, 10 mM NaCl, 
3 mM MgClz). The lysate was resuspended in 10 ml Buffer II (10 mM 
Hepes, pH 7.9, 10 mM NaCl, 3 mM MgCl2) and sedimented twice 
through 10 ml 30% sucrose in Buffer II at 1000 x g at 4°C for 5 min. 
Nuclei were resuspended in 3 ml Buffer III (20 mM Hepes pH 7.9, 
0.42 M NaCl, 1.5 mM MgClz, 0.2 mM EDTA, 0.5 mM DTT, 
0.5 mM PMSF, 25% glycerol) and the protein extract prepared as 
described by Wildeman [20] apart from the addition of 0.5 mM 
PMSF to the buffers used. Typically 5-10 mg’mll’ protein was ob- 
tained from 10’ cells and stored in aliquots at -70°C. 
2.4. Oligonucleotides and probe preparation 
The oligonucleotide ‘ag2’ derived from mouse cyr-globin was a gift 
from Dr M. Plumb (Beatson Institute, Glasgow). Other 
oligonucleotides (antisense strand shown below) were made as com- 
plementary single-stranded sequences and annealed before use: 
Oligo A: 5 ’ GTATTTTTATTGATTATTGTGCTG-3 ’ 
Oligo B: 5 ‘-ACCACTTCCC TTATCAGGTTCTC-3 ’ 
Oligo C: 5 ’ CCCACTCTAATCA CCACAGGGCCA-3 ’ 
Oligo E: 5 ’ -TGATCAAATGATTATCT TTTATAT-3 ’ 
Oligo F: 5’-CTATTT WTTAATTGACACA-3 ’ 
Oligo cug2: 5’-GATCCGGGCAAC TGATAAGGATTCCC- 
AGATC-3’ 
Oligo CACCC: 5 ‘-CTGATTAAAT-CA-3 ’ 
The oligonucleotides were 5 ’ -end labelled as above and 5 ‘-overhangs 
were filled in using excess dNTPs and Klenow fragment and purified 
by electrophoresis on a 10% polyacrylamide gel. 
Fragment ‘D’, a 57 bp NheI-EcoRI fragment (195-251 bp 
downstream from the ‘stop’ codon) which lies between the two 
polyadenylation sites, was dephosphorylated using calf intestinal 
phosphatase and 32P end-labelled as above. 
2.5. Gel retardation assay 
Gel retardation assays using whole cell extracts were carried out 
essentially as described by Dale et al. (191. 10 pl of extract was prein- 
cubated with 1 pl of 5 mg . ml-’ poly(dI-dC) poly(dI-dC) for 15 min 
at 20°C. Additional components were added to a final concentration 
of 0.5 x Buffer B, 2% Ficoll (w/v), 0.25 mg’ml-’ BSA, 
10-20000 cpm end-labelled DNA and 100 ng competitor DNA where 
indicated in a final volume of 40 pl. The mixture was incubated for 
a further 15 min at 20°C. Samples were electrophoresed on a 5% 
nondenaturing polyacrylamide gel in 0.5 x TBE (89 mM Tris, 89 mM 
boric acid and 5 mM EDTA) at 150 V for 2 h. 
2.6. Footprinting analysis 
The 255 bp PvuII-AvaII fragment (-219 to +35) was subcloned 
into the SmaI site of Bluescript plasmid (KS + , Stratagene). Both 
strands were labelled for DNase I footprinting of the promoter region 
of HCAI: the coding and noncoding strands were 5 ’ -end labelled at 
the polylinker Hind111 site and the DdeI site at + 14, respectively, and 
fragments were purified after secondary digestion with HaeII (- 107) 
for the coding strand and with PstI (in the polylinker) for the non- 
coding strand. Markers were prepared by Maxam-Gilbert sequencing 
of the 5’-end labelled fragments. 
Nuclear protein (So-100 pg) was preincubated with 1 pg poly(dI- 
dC) poly(dI-dC) in 40 pl binding buffer (50 mM KCl, 5 mM MgCl2, 
1 mM EDTA, 10 mM Tris-HCl pH 8.0, 1 mM DTT, 12.5% glycerol 
and 0.1% Triton X-100) at 4°C for 30 min. Labelled fragments 
(20000 cpm) were added and incubated at 4°C for 30 min. DNase I 
digestion at 0.5 pg. ml -I, in the presence of protein and 0.01 pg.ml-’ 
in the absence of protein, was at 20°C for 2 min, followed by the ad- 
dition of 0.1 vol. of ‘stop’ solution (1 mM EDTA, 10% SDS, 
1 mg’ml-’ tRNA). DNA was purified by organic extraction and 
resolved on an 8% denaturing polyacrylamide gel. 
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2.7. Transfection 
F412B2 MEL cells and HeLa cells were transfected using calcium 
phosphate/DNA precipitation as described by Rosenthal [21]. 1.5 x 
lo6 F412B2 cells were plated on 100 mm Corning tissue culture dishes 
(Bibby) 20-22 h before transfection whereas 3 x lo6 HeLa cells were 
plated on 75 cm’ Falcon tissue culture flasks (Becton and Dickinson) 
at the equivalent time. The precipitate was left in contact with 
F412B2 cells for 24 h and with HeLa cells for 6 h, followed by 
glycerol shock for 2 min. Both types of cell were left for 48 h after 
adding the precipitate before harvesting. Cell lysates were then made 
by 3 cycles of freeze-thawing. 
2.8. Chloratnphenicolacetyl transferase (CA T) and ,8-galactosidase 
assays 
P-Galactosidase assays were performed exactly as described by 
Herbomel et al. [22]. Equivalent amounts of ,&galactosidase activity 
for each transfected plate or flask were then assayed for CAT activity 
exactly as described by Gorman et al. [23]. 
2.9. Northern analysis 
RNA was separated and transferred onto Gene Screen Plus [24]. 
HCAI mRNA was detected by hybridising the filter with 1 x 10’ cpm 
HCAI cDNA [25] labelled with [y-32P]dCTP using random primers. 
Hybridisation and washing conditions were as recommended for 
Gene Screen Plus. 
3. RESULTS AND DISCUSSION 
S-mapping and primer extension studies have defin- 
ed the position of the 5’-end of the transcription unit 
(fig.lA,B). Si-mapping has also identified the 
polyadenylation site, pA(I1) at the 3’-end of the most 
abundant HCAI mRNA species (fig.lC) which lies 
225 bp downstream from an alternative (yet rarely us- 
ed) site of 3’-end maturation, PA(I), previously 
described from an analysis of cDNA clones [25]. Con- 
sensus sequences for the binding of general transcrip- 
tion factors are apparent (fig.lD). At -28 there is a 
globin-like ‘CATA’ motif [26] and three potential 
‘CAAT’ box sequences [26] between -60 and -90. 
The flanking sequences also contain consensus binding 
sites for characterised transcription factors: for the 
‘CACCC-binding factor [27] at -209 and -47; for 
AP-1 [28] at -324 and 801 bp downstream from the 
end of the protein-coding sequence; for Spl [29] at -93 
and Ott-1 [30] at -81. Based on previously reported 
consensus sequences [3-51 for the binding of an 
erythroid-specific transcription factor, GF-1, six poten- 
tial sites are found flanking the HCAI gene: sites A, B 
and C at -290, - 190 and - 149, respectively, and sites 
D, E and F located 223 bp, 581 bp and 833 bp 
downstream from the ‘stop’ codon. Site D lies between 
the two polyadenylation sites and site E has the se- 
quence motif in two orientations. 
Gel retardation assays show that all six GATAAG- 
like sequences flanking the HCAI transcription unit 
bind the same erythroid-specific protein (fig.2). 
Double-stranded oligonucleotides (23- or 24-mers) con- 
taining sites A, B, C, E and F and a 57 bp fragment 
containing site D were used. Each gives rise to a ban- 
ding pattern containing a more abundant upper band 
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and a much less abundant lower band when incubated motif) shows binding to be specific to 
with a protein extract from erythroid (MEL) cells. In like motif (lanes 15-26). Protein 
each case, competition using Oligo-B or Oligo-crg2 (in erythroid cell lines regardless of 
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the GATAAG- 
extracts from 
developmental 
which the only common sequence is a GATAAG-like phenotype (K562, K562-SAl, MEL and HEL, lanes 1, 
A. Sf map of HCAI 5’ end 
(-219) (-13.5) 
&f& &gJ! +1 +52 
B. Primer extension analysis of C. ST map of HCAI 3’ end 
HCAI 5’ end 
(221) (334) (572) 
+’ 
lasnt 5s probe R 
52nt RNA-protected--W 
Probe 
--Y Primer 
x:::: :: - 
- 52nt RNA-protected 1, 
Pro& 
T 
366nt ss probe 
1lOnt RNA-protected 
P’h 
nt nt 
D. (i) 5’-region flanking the transcription start site 
XP- I GFl (A) 
-360 TGAGTTCAAAATCGACATCAAGA7ATAAAGGAATCAGTGAC7AAATA7AT~CATATATGGTATTTTfAtTGATTATTGTGC7GTCTTGACC7AG7ATGG 
T&l 
‘CACCC’ GFl(B) 
-260 AGGCCTTGGCTAGAGGCTGGTCAGTTTCC7C7C77GAGCAGCTGA77AAA7CCACACCCCAACCAC77CC~G6T7CTCACAC7CTGGGGCCACT 
?vk I: 
GFl(C) SD1 Oet-7 
-160 ATGTACCCACTCTAATtftCCACAGGGCCAGACATCAGACAATTAAGGACAGCGCCCATGCCCCAAAG~AAAATTATGCAAATTATTCAAAATTAT 
&a 1 Ihe- I I Ha;11 ’ CAAT ’ ‘GAIT’ ‘CAAT’ 
‘CACCC’ ‘TATA’ *I 
- 60 TCAACC7AGCTAACCCCACCCTT777GCTGTACATAAGC7GCCCATTCCCCCTCCAGCCT~7GGTACCCAG7CCTCAGG7GCAACCCCCTGCGTGGTCCT 
OIL1 
(ii) 3’ region flanking the translation stop signa 
Arg Ala Scr Pht CfS CTS PA(I) 
AGA-GCT.TCA.TTT.TGA.TGA ---------------------------- i 77 ?TTTTAAGA~TTTAT7TCAATATlAGC~AGACAGCATGCC ------- 
GFl(O1 vA(JI) 
----- TCTGTAAGCATAAGCTTATCTTAAATTCAA TATTTGAACCAATAAAATAATTTTATCTCTTTCTTTCTGTTGTGCATTCAGTTTCTA ----- ----- 
269 302 
GFliE) AP-I GFIJF) 
----- ~GATCAAAATGATTATCTTTTATAT CAATCTTTTA67CAGATGTGCCCrfCAECTTAiOCrAfrTTTATCTTTAATTGACACA ------- 
5i2 
------- 
7&l 
Fig. 1. The HCAI transcription unit. (A) $-mapping and (B) primer extension analysis defining the transcription start site. (C) SI-mapping of 
the most 3’-polyadenylation site. (D) DNA sequences flanking the 5’- and 3’-end of the HCAI transcription unit showing relevant restriction 
endonuclease cleavage sites and consensus sequences for binding of ubiquitous and ceil-type specific transcription factors and for 3’-end 
maturation. 
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Protein : SEL &La t4BL 1(3b‘ SAI X562 HUT HLbO 
Oliqo probe: B * 
cmpet.tor : - F - F - F - F - F - F - F 
MEL * 
BBAACCEE FFD D 
-aq2 - B - S - B - B - 6 
I2345 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 
Fig.2. The binding of factors to CATAAG-like sequences flanking the HCAI gene. Gel retardation assays of 5’-end Iabelled double-stranded 
oligonucleotides with 5Opg protein extracts from erythroid and non-erythroid cell lines. Competition assays were performed with 150 ng 
unlabelled double-stranded oligonucleotides as specified. Those involving IabeIIed otigo-B give rise to a characteristic band which does not occur 
with any of the other oligonucleotide probes used. 
SPlI 
act-I 
I 
CACCC 
I 
Non-codinq Coding 
Fig.3. Footprint analysis of the -219 to +I4 region of the HCAl 
gene. T + C indicates Maxam-Gilbert sequencing reactions; ‘0 
indicates DNase I digestion without protein. The boxes to the left of 
the panels denote the footprint around each consensus: CACCC 
(-209 and -471, GF-1 binding sites B and C (-190 and -149, 
respectively), Spl (-93) and Ott-1 (-81). (A) Analysis of the non- 
coding strand from PvulI (-219) to (+14) after binding with HEL* 
(5Opg) and HEL (IOOpg), HeLa (IOO~g) or HUT-78 (IOOpg) 
nuclear extracts. Competition of the footprint over GF-I (site B) in 
HEL extracts was by the addition of 200 ng double-stranded 
oligonucleotide B or ag2. (B) Analysis of the coding strand from 
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2, 5-10) all contain the factor (forming complexes with 
Oligo-B which are competed out by Oligo-F); thus the 
factor is present in erythroid cells even in embryonic 
cells in which HCAI is not expressed (see IS]). The fac- 
tor is absent from non-erythroid haemopoietic cells 
(HL-60 and HUT-78, lanes 11-14). HeLa cells do not 
have the same factor; however, this non-erythroid cell 
line does contain a small amount of a protein which 
forms a lower molecuIar weight compIex with the 
GATAAG motif in Oligo-B (competed by Oligo-F, 
lanes 3 and 4). Comparing the six binding sites with the 
other published consensus equences [3-51 suggests a 
core recognition site of 3 ’ -Py-z-A-T-C-?-5 ’ . 
DNase I footprinting of the HCAI promoter region 
by HEL, HeLa and HUT-78 nuclear proteins (fig.3) 
shows protection around the GATAAG motif at Site B, 
exclusively with proteins from erythroid cells. The 
region between - 193 and - 179 containing Site B is 
footprinted by HEL cell proteins with the induction of 
a hypersensitive site at -180. The footprint is 
specifically competed out by the addition of GATAAG 
motif-containing double-stranded oligonucleotides B 
and crg2 but not the ‘CACCC’ oligonucleotide. No 
footprint is evident on either DNA strand for Site C at 
-150 which suggests non-equivalence in function bet- 
ween the multiple GATAAG-like elements. Footprints 
over the Sp-1, Ott-1 and ‘CACCC’ consensus se- 
quences are also observed which are not erythroid 
specific [26,28,29]. 
To show in vivo effects of erythroid specific factor 
binding, the 5 ’ TagI-Z&I fragment ( -348 to - 157) of 
PvuII (-219) to Hue11 (-107) after binding with protein extracts 
from HEL (1OOpg) and HeLa (100 pg); competitor for footprint at 
site B was 200 ng Oligo-B. 
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6346l w5n 
m flu pHCA1 CAT T/R 
m Ilm pHCAICAT R/T 
\xbaI/ 
pEL CAT2 tk 1 CAT 
Fig.4. Tuql-RsaI fragment of HCAI (-348 to -157) inserted (in 
either orientation) into the unique X&I site of pBLCAT2, upstream 
of a minimal thymidine kinase (tk) promoter fused to the CAT 
reporter gene, the SV40 small t intron and polyadenylation site. 
HCAI was placed in either orientation into an expres- 
sion vector upstream of the minimal thymidine kinase 
promoter [31] fused to the CAT reporter gene il- 
lustrated in fig.4. Constructs cont~ning the HCAI 
fragment, or vector alone, were cotransfected into cells 
with a plasmid containing the ,&galactosidase reporter 
gene driven by the herpes simplex virus immediate arly 
gene 4 promoter to normalise transfection efficiency. 
The transfected cells were MEL F412B2 cells which ex- 
press mouse CA1 and HeLa cells which do not express 
CAL The plasmid containing the TagI-&@ fragment 
of HCAI shows a 2.5-2.8-fold induction over the con- 
trol plasmid in MEL cells but not in HeLa cells (table 
1). This fragment which flanks the 5’-end of the HCAI 
gene contains two GATAAG-like motifs (Sites A and 
B), and consensus equences for AP-1 and ‘CACCC’ 
binding proteins. However, ‘CACCC’-box and AP-1 
binding proteins are present in both HeLa [27,28] and 
MEL cells [4,32]. 
HEL cells constitutively express HCAI. When 
treated with the phorbol ester TPA, a shift takes place 
from erythroid to myeloid lineage as evidenced by the 
morphologica1, biochemical and functional changes 
they undergo [17]. Northern analysis (fig.5) shows that 
the treatment of HEL cells with TPA reduces the 
steady-state level of HCAI mRNA 7-S-fold compared 
with untreated HEL cells (from scanning den- 
sitometry). This is in contrast to the induction of CA11 
mRNA observed in TPA-treated HL60 cells 1331 which 
Table 1 
Effect of an HCAI 5’-flanking region on minimal promoter function 
HeLa F4 
pBL CAT2 1.0 1.0 
pHCAI CAT T/R 0.5 2.8 
pHCA1 CAT R/T 0.9 2.5 
Each construct (iIlustra~ed in fig.4) was transfected separately into 
HeLa and MEL F412B2 (F4) cells. Normalised volumes of extracts 
from transfected cells (see section 2) were assayed for CAT activity 
and subsequently analysed by scanning densitometry. The data 
derived from each construct are given relative to pBL-CAT2 in each 
cell line 
c +TPA +DMso 
Days of 
treatment 
0 48 48 
t- 
Fig.5. Northern analysis of equivalent amount of total RNA from 
control and TPA-treated HEL cells probed with 32P-labelled HCAI 
cDNA. 
indicates a difference in the regulation of CA1 and 
CA11 transcription. However, gel retardation assays 
with protein extracts from TPA-treated and control 
HEL cell cultures show no change in the binding pat- 
tern of the erythroid factor to Oligo-B (data not 
shown). 
The presence of the erythroid factor in TPA-treated 
HEL cells in which the level of HCAI transcript has 
greatly decreased and in non-expressing K562 cells sug- 
gests that the presence of the erythroid factor (GF-1) is 
not sufficient for HCAI expression. 
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